[go: up one dir, main page]

PE20060009A1 - Metodos y composiciones para el tratamiento de tumores y enfermedades metastasicas - Google Patents

Metodos y composiciones para el tratamiento de tumores y enfermedades metastasicas

Info

Publication number
PE20060009A1
PE20060009A1 PE2005000129A PE2005000129A PE20060009A1 PE 20060009 A1 PE20060009 A1 PE 20060009A1 PE 2005000129 A PE2005000129 A PE 2005000129A PE 2005000129 A PE2005000129 A PE 2005000129A PE 20060009 A1 PE20060009 A1 PE 20060009A1
Authority
PE
Peru
Prior art keywords
treatment
integrin
methods
compositions
tumors
Prior art date
Application number
PE2005000129A
Other languages
English (en)
Inventor
Nancy Wehner
Original Assignee
Elan Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Elan Pharm Inc filed Critical Elan Pharm Inc
Publication of PE20060009A1 publication Critical patent/PE20060009A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/541—Non-condensed thiazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • C07K16/2842—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily against integrin beta1-subunit-containing molecules, e.g. CD29, CD49
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Mycology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Hematology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

SE REFIERE A COMPOSICIONES QUE INCLUYEN UNA INMUNOGLOBULINA ANTI INTEGRINA a4 O UNA INMUNOGLOBULINA A UN LIGANDO INTEGRINA a4 (POR EJEMPLO, MadCAM-1 y VCAM-1), SIENDO PREFERIDO EL ANTICUERPO ANTI-a4 QUE SE UNE A LA INTEGRINA a4b1 Y/O A LA INTEGRINA a4b7, TAL COMO EL ANTICUERPO MONOCLONAL NATALIZUMAB, ADMINISTRANDOSE EN CONCENTRACIONES DE APROXIMADAMENTE DE 1 MG/KG A 100 MG/KG DEL PESO DEL INDIVIDUOO; PUEDEN ADMINISTRARSE SOLOS O COMBINADOS CON OTROS REACTIVOS Y CON OTRAS MODALIDADES DE TRATAMIENTO DEL CANCER. TAMBIEN SE REFIERE A METODOS Y TERAPIAS COMBINADAS PARA EL TRATAMIENTO DE CANCERES QUE IMPLICAN LA EXPRESION DE UNA INTEGRINA a4 COMO LINFOMAS, LEUCEMIA, MELANOMAS, CANCER DE PROSTATA Y ENFERMEDADES METASTICAS
PE2005000129A 2004-02-06 2005-02-04 Metodos y composiciones para el tratamiento de tumores y enfermedades metastasicas PE20060009A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US54194604P 2004-02-06 2004-02-06

Publications (1)

Publication Number Publication Date
PE20060009A1 true PE20060009A1 (es) 2006-02-11

Family

ID=34860234

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2005000129A PE20060009A1 (es) 2004-02-06 2005-02-04 Metodos y composiciones para el tratamiento de tumores y enfermedades metastasicas

Country Status (19)

Country Link
US (1) US20050255118A1 (es)
EP (2) EP1718310A4 (es)
JP (1) JP4996261B2 (es)
KR (1) KR20070009581A (es)
CN (1) CN1946407B (es)
AR (1) AR047534A1 (es)
AU (1) AU2005213324B2 (es)
BR (1) BRPI0507451A (es)
CA (1) CA2555365A1 (es)
EA (1) EA009873B1 (es)
IL (1) IL177201A0 (es)
MX (1) MXPA06008746A (es)
NO (1) NO20063951L (es)
NZ (1) NZ584288A (es)
PE (1) PE20060009A1 (es)
TW (1) TWI375563B (es)
UY (1) UY28741A1 (es)
WO (1) WO2005076843A2 (es)
ZA (1) ZA200606557B (es)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TR201808801T4 (tr) 2003-02-10 2018-07-23 Biogen Ma Inc İmmünoglobulin formülasyonu ve bunun hazırlanış yöntemi.
MX350383B (es) 2004-01-09 2017-09-04 Pfizer Anticuerpos contra madcam.
WO2007007152A2 (en) * 2005-07-11 2007-01-18 Pfizer Limited Anti-madcam antibodies to treat metastatic cancers and chloroma
ES2627923T3 (es) 2007-01-11 2017-08-01 Novo Nordisk A/S Anticuerpos anti-KIR, formulaciones y usos de los mismos
JP2011506322A (ja) * 2007-12-07 2011-03-03 エラン ファーマシューティカルズ，インコーポレイテッド 液性腫瘍を治療するための方法および組成物
GB0800311D0 (en) * 2008-01-09 2008-02-20 Cytosystems Ltd Apparatus and method for filtering biological material
WO2009129333A1 (en) * 2008-04-15 2009-10-22 Oxigene, Inc. Methods for enhancing the efficacy of vascular disrupting agents
US20100158893A1 (en) * 2008-12-19 2010-06-24 Baxter International Inc. Systems and methods for obtaining immunoglobulin from blood
JP2013525260A (ja) * 2009-04-17 2013-06-20 バイオジェン・アイデック・エムエイ・インコーポレイテッド 急性骨髄性白血病を治療するための組成物および方法
US20110158982A1 (en) * 2009-10-05 2011-06-30 The Regents Of The University Of Michigan COMPOSITIONS AND METHODS FOR INHIBITING MAdCAM
WO2012048298A2 (en) 2010-10-08 2012-04-12 Caridianbct, Inc. Methods and systems of growing and harvesting cells in a hollow fiber bioreactor system with control conditions
RS66261B1 (sr) 2010-10-25 2024-12-31 Biogen Ma Inc Postupci za određivanje razlika u aktivnosti alfa-4 integrina uspostavljanjem korelacije sa razlikama u nivoima svcam i/ili smadcam
MX368261B (es) 2011-07-22 2019-09-25 Pacylex Pharmaceuticals Inc Letalidad sintetica y el tratamiento de cancer.
EP3795145A3 (en) 2011-08-17 2021-06-09 Dennis M. Brown Compositions and methods to improve the therapeutic benefit of suboptimally administered chemical compounds including substituted hexitols such as dibromodulcitol
WO2014018913A2 (en) * 2012-07-27 2014-01-30 University Of Connecticut Santacruzamate a compositions and analogs and methods of use
US9657105B2 (en) 2013-03-15 2017-05-23 City Of Hope CD123-specific chimeric antigen receptor redirected T cells and methods of their use
RU2527154C1 (ru) * 2013-03-27 2014-08-27 Федеральное государственное бюджетное учреждение "Ростовский научно-исследовательский онкологический институт" Министерства здравоохранения Российской Федерации Способ повышения биодоступности цисплатина в саркому -45, индуцированную в эксперименте
ES2728305T3 (es) * 2013-04-29 2019-10-23 Ogd2 Pharma Uso como diana del gangliosido GD2 O-acetilado como una nueva estrategia terapéutica y de diagnóstico para cáncer de células madre cancerosas
WO2015073918A1 (en) 2013-11-16 2015-05-21 Terumo Bct, Inc. Expanding cells in a bioreactor
JP6855243B2 (ja) 2014-01-24 2021-04-07 エイアイ・セラピューティクス・インコーポレーテッド 癌治療のためのアピリモド（ａｐｉｌｉｍｏｄ）組成物
JP6783143B2 (ja) 2014-03-25 2020-11-11 テルモ ビーシーティー、インコーポレーテッド 培地の受動的補充
CN106715676A (zh) 2014-09-26 2017-05-24 泰尔茂比司特公司 按计划供养
AU2015342863B2 (en) 2014-11-07 2021-01-21 AI Therapeutics, Inc. Apilimod for use in the treatment of melanoma
JP6705828B2 (ja) 2014-11-07 2020-06-03 エイアイ・セラピューティクス・インコーポレーテッド 腎癌の処置に使用するためのアピリモド
WO2017004592A1 (en) 2015-07-02 2017-01-05 Terumo Bct, Inc. Cell growth with mechanical stimuli
US11788145B2 (en) 2015-07-17 2023-10-17 Pacylex Pharmaceuticals Inc. Epigeneiic silencing of NMT2
CN109415696A (zh) 2016-05-25 2019-03-01 泰尔茂比司特公司 细胞扩增
US11104874B2 (en) 2016-06-07 2021-08-31 Terumo Bct, Inc. Coating a bioreactor
US11685883B2 (en) 2016-06-07 2023-06-27 Terumo Bct, Inc. Methods and systems for coating a cell growth surface
US12234441B2 (en) 2017-03-31 2025-02-25 Terumo Bct, Inc. Cell expansion
US11629332B2 (en) 2017-03-31 2023-04-18 Terumo Bct, Inc. Cell expansion
US11624046B2 (en) 2017-03-31 2023-04-11 Terumo Bct, Inc. Cell expansion
RU2650587C1 (ru) * 2017-04-26 2018-04-16 Федеральное государственное бюджетное учреждение "Ростовский научно-исследовательский онкологический институт" Министерства здравоохранения Российской Федерации Способ модификации хронической болью злокачественного роста меланомы в16 у мышей
JP7160491B2 (ja) 2017-07-14 2022-10-25 ファイザー インコーポレイティッド ＭＡｄＣＡＭに対する抗体
CN113166225A (zh) * 2018-09-13 2021-07-23 恩卡尔塔公司 天然杀伤细胞组合物和治疗肿瘤的免疫疗法方法
CN118546960A (zh) 2019-03-05 2024-08-27 恩卡尔塔公司 Cd19定向性嵌合抗原受体及其在免疫疗法中的用途
GB2619893A (en) 2021-03-23 2023-12-20 Terumo Bct Inc Cell capture and expansion
RU2762730C1 (ru) * 2021-03-30 2021-12-22 Елена Рудольфовна Милаева Средство для ингибирования метастазирования в легких
RU2765955C1 (ru) * 2021-03-30 2022-02-07 Елена Рудольфовна Милаева Средство для ингибирования метастазирования в легких
US12209689B2 (en) 2022-02-28 2025-01-28 Terumo Kabushiki Kaisha Multiple-tube pinch valve assembly
USD1099116S1 (en) 2022-09-01 2025-10-21 Terumo Bct, Inc. Display screen or portion thereof with a graphical user interface for displaying cell culture process steps and measurements of an associated bioreactor device
WO2024186193A1 (ko) * 2023-03-08 2024-09-12 인제대학교 산학협력단 국소적 방사선 치료에서 전신성 항암 치료를 위한 조성물
WO2024249568A1 (en) 2023-05-30 2024-12-05 Paragon Therapeutics, Inc. Alpha4beta7 integrin antibody compositions and methods of use

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4485045A (en) 1981-07-06 1984-11-27 Research Corporation Synthetic phosphatidyl cholines useful in forming liposomes
US4544545A (en) 1983-06-20 1985-10-01 Trustees University Of Massachusetts Liposomes containing modified cholesterol for organ targeting
HUT35524A (en) 1983-08-02 1985-07-29 Hoechst Ag Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance
US6033665A (en) 1989-09-27 2000-03-07 Elan Pharmaceuticals, Inc. Compositions and methods for modulating leukocyte adhesion to brain endothelial cells
CA2072249C (en) 1991-06-28 2003-06-17 Saiko Hosokawa Human monoclonal antibody specifically binding to surface antigen of cancer cell membrane
EP0678122B1 (en) * 1993-01-12 1999-07-28 Biogen, Inc. Recombinant anti-vla4 antibody molecules
US5840299A (en) 1994-01-25 1998-11-24 Athena Neurosciences, Inc. Humanized antibodies against leukocyte adhesion molecule VLA-4
AU3559695A (en) 1994-09-30 1996-04-26 Inex Pharmaceuticals Corp. Glycosylated protein-liposome conjugates and methods for their preparation
US6551593B1 (en) 1995-02-10 2003-04-22 Millennium Pharmaceuticals, Inc. Treatment of Inflammatory bowel disease by inhibiting binding and/or signalling through α 4 β 7 and its ligands and madcam
EP1019064A4 (en) * 1997-02-28 2006-11-08 Univ California Inhibition of cell-cell binding by lipid assemblies
MY153569A (en) * 1998-01-20 2015-02-27 Mitsubishi Tanabe Pharma Corp Inhibitors of ?4 mediated cell adhesion
NZ511062A (en) * 1998-09-14 2003-04-29 Univ Texas Antagonists of alpha4 containing integrins, which inhibit the biological effects of adhesion interaction in myeloma bone disease
NZ519447A (en) 1999-12-16 2004-03-26 Biogen Inc Methods of treating central nervous system ischemic or hemorrhagic injury using anti alpha4 integrin antagonists
AU2002239486A1 (en) * 2000-12-08 2002-06-18 Uab Research Foundation Combination radiation therapy and chemotherapy in conjuction with administration of growth factor receptor antibody
WO2002100428A1 (en) * 2001-06-11 2002-12-19 Transition Therapeutics Inc. Combination therapies using vitamin b12 and therapeutic agents for treatment of viral, proliferative and inflammatory diseases
EP1423135A4 (en) * 2001-08-06 2006-06-07 Univ California METHODS OF INHIBITING ANGIOGENESIS
EP3674322A1 (en) * 2002-02-25 2020-07-01 Biogen MA Inc. Administration of agents for the treatment of inflammation
CN1878568A (zh) * 2003-11-05 2006-12-13 盘林京有限公司 Cdim结合抗体的增强的b细胞细胞毒性
EP1701979A2 (en) * 2003-12-03 2006-09-20 Xencor, Inc. Optimized antibodies that target the epidermal growth factor receptor

Also Published As

Publication number Publication date
EP2394652A2 (en) 2011-12-14
JP2007520557A (ja) 2007-07-26
BRPI0507451A (pt) 2007-07-10
WO2005076843A2 (en) 2005-08-25
WO2005076843A3 (en) 2006-01-26
NO20063951L (no) 2006-11-02
CN1946407B (zh) 2011-10-05
EA200601433A1 (ru) 2007-02-27
CA2555365A1 (en) 2005-08-25
AR047534A1 (es) 2006-01-25
AU2005213324A1 (en) 2005-08-25
AU2005213324B2 (en) 2011-06-09
EP1718310A4 (en) 2009-05-06
EA009873B1 (ru) 2008-04-28
EP1718310A2 (en) 2006-11-08
TWI375563B (en) 2012-11-01
IL177201A0 (en) 2006-12-10
EP2394652A3 (en) 2012-10-24
CN1946407A (zh) 2007-04-11
TW200536556A (en) 2005-11-16
KR20070009581A (ko) 2007-01-18
US20050255118A1 (en) 2005-11-17
NZ584288A (en) 2011-10-28
JP4996261B2 (ja) 2012-08-08
MXPA06008746A (es) 2007-01-23
UY28741A1 (es) 2005-08-31
ZA200606557B (en) 2008-02-27

Similar Documents

Publication Publication Date Title
PE20060009A1 (es) Metodos y composiciones para el tratamiento de tumores y enfermedades metastasicas
Nagayama et al. Novel antibody–drug conjugates for triple negative breast cancer
Pierro et al. New targeted therapies for relapsed pediatric acute lymphoblastic leukemia
UY28028A1 (es) Anticuerpos que enlazan a células asociadas ca 125/0772p y metodos de uso derivados
UA114879C2 (uk) Антитіло до cd38 для лікування раку
MX2019013033A (es) Formulaciones estables de anticuerpos anti-tigit solos y en combinacion con anticuerpos anti-receptor de muerte programada 1 (pd-1) y metodos para su uso.
Lettieri et al. Progress and opportunities for immune therapeutics in osteosarcoma
TN2019000294A1 (en) Stable formulations of anti-ctla4 antibodies alone and in combination with programmed death receptor 1 (pd-1) antibodies and methods of use thereof
NZ731633A (en) Antibodies against cd73 and uses thereof
TN2009000007A1 (en) Antagonist antibody against epha2 for the treatment of cancer
PH12013502043A1 (en) T cell receptor-like antibodies specific for a wt1 peptide presented by hla-a2
MX2009006275A (es) Anticuerpos humanos que enlazan con cd19 y sus usos.
Hayashi et al. Gemcitabine enhances rituximab‐mediated complement‐dependent cytotoxicity to B cell lymphoma by CD20 upregulation
Sha et al. Chimaeric antigen receptor T-cell therapy for tumour immunotherapy
EA200970884A1 (ru) Способы лечения рака путем введения комбинаций человеческого интерлейкина ил-18
Joy et al. Recent advances and current challenges in CAR-T cell therapy
Murar et al. Cancer stem cell markers: premises and prospects
Dettling et al. Regression of EGFR positive established solid tumors in mice with the conditionally active T cell engager TAK-186
Maciocia et al. Anti-CD21 chimeric antigen receptor (CAR)-T cells for T cell acute lymphoblastic leukaemia (T-ALL)
Roberts et al. Therapeutic targeting of the thrombospondin-1 receptor CD47 to treat liver cancer
Chung et al. CD99 is a therapeutic target on disease stem cells in acute myeloid leukemia and the myelodysplastic syndromes
Noraldeen et al. Involving stemness factors to improve CAR T-cell-based cancer immunotherapy
Dittmar et al. Role of cancer stem cells in cancer biology and therapy
Balduzzi et al. Acute lymphoblastic leukaemia in the youngest: haematopoietic stem cell transplantation and beyond
Maugeri-Saccà et al. Cancer stem cells: are they responsible for treatment failure?

Legal Events

Date Code Title Description
FC Refusal